Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: BUY (auto-tracking)
1.38% $29.38
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 298.10 mill |
EPS: | 0.840 |
P/E: | 34.98 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 78.22 mill |
Avg Daily Volume: | 0.725 mill |
RATING 2024-04-23 |
---|
A+ |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 34.98 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.16x |
Company: PE 34.98 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
$36.09 (22.85%) $6.71 |
Date: 2024-04-23 |
Expected Trading Range (DAY) |
---|
$ 28.34 - 30.42 ( +/- 3.55%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-11 | De Witte Jan | Buy | 41 414 | Restricted Stock Units |
2024-03-11 | De Witte Jan | Sell | 205 | Restricted Stock Units |
2024-03-11 | De Witte Jan | Buy | 95 664 | Non- Qualified Stock Option (right to buy) |
2024-03-11 | De Witte Jan | Buy | 205 | Common Stock |
2024-03-11 | De Witte Jan | Sell | 205 | Common Stock |
INSIDER POWER |
---|
80.45 |
Last 97 transactions |
Buy: 599 911 | Sell: 62 631 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $29.38 (1.38% ) |
Volume | 1.007 mill |
Avg. Vol. | 0.725 mill |
% of Avg. Vol | 138.80 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $41.57 | N/A | Active |
---|
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.